Jim O'Doherty1, Maite Jauregui-Osoro1, Teresa Brothwood2, Teresa Szyszko1, Paul K Marsden1, Michael J O'Doherty1, Gary J R Cook1, Philip J Blower1, Val Lewington3. 1. PET Imaging Centre, Division of Imaging Sciences and Biomedical Engineering, King's College London, St. Thomas' Hospital, London, United Kingdom; and. 2. Department of Nuclear Medicine, Guy's & St. Thomas' Hospital NHS Foundation Trust, Great Maze Pond, London, United Kingdom. 3. Department of Nuclear Medicine, Guy's & St. Thomas' Hospital NHS Foundation Trust, Great Maze Pond, London, United Kingdom val.lewington@gstt.nhs.uk.
Abstract
We report the safety, biodistribution, and internal radiation dosimetry, in humans with thyroid cancer, of 18F-tetrafluoroborate (18F-TFB), a novel PET radioligand for imaging the human sodium/iodide symporter (hNIS). Methods: Serial whole-body PET scans of 5 subjects with recently diagnosed thyroid cancer were acquired before surgery for up to 4 h after injection of 184 ± 15 MBq of 18F-TFB. Activity was determined in whole blood, plasma, and urine. Mean organ-absorbed doses and effective doses were calculated via quantitative image analysis and using OLINDA/EXM software. Results: Images showed a high uptake of 18F-TFB in known areas of high hNIS expression (thyroid, salivary glands, and stomach). Excretion was predominantly renal. No adverse effects in relation to safety of the radiopharmaceutical were observed. The effective dose was 0.0326 ± 0.0018 mSv/MBq. The critical tissues/organs receiving the highest mean sex-averaged absorbed doses were the thyroid (0.135 ± 0.079 mSv/MBq), stomach (0.069 ± 0.022 mSv/MBq), and salivary glands (parotids, 0.031 ± 0.011 mSv/MBq; submandibular, 0.061 ± 0.031 mSv/MBq). Other organs of interest were the bladder (0.102 ± 0.046 mSv/MBq) and kidneys (0.029 ± 0.009 mSv/MBq). Conclusion: Imaging using 18F-TFB imparts a radiation exposure similar in magnitude to many other 18F-labeled radiotracers. 18F-TFB shows a biodistribution similar to 99mTc-pertechnetate, a known nonorganified hNIS tracer, and is pharmacologically and radiobiologically safe in humans. Phase 2 trials for 18F-TFB as an hNIS imaging agent are warranted.
We report the safety, biodistribution, and internal radiation dosimetry, in humans with thyroid cancer, of 18F-tetrafluoroborate (18F-TFB), a novel PET radioligand for imaging the human sodium/iodide symporter (hNIS). Methods: Serial whole-body PET scans of 5 subjects with recently diagnosed thyroid cancer were acquired before surgery for up to 4 h after injection of 184 ± 15 MBq of 18F-TFB. Activity was determined in whole blood, plasma, and urine. Mean organ-absorbed doses and effective doses were calculated via quantitative image analysis and using OLINDA/EXM software. Results: Images showed a high uptake of 18F-TFB in known areas of high hNIS expression (thyroid, salivary glands, and stomach). Excretion was predominantly renal. No adverse effects in relation to safety of the radiopharmaceutical were observed. The effective dose was 0.0326 ± 0.0018 mSv/MBq. The critical tissues/organs receiving the highest mean sex-averaged absorbed doses were the thyroid (0.135 ± 0.079 mSv/MBq), stomach (0.069 ± 0.022 mSv/MBq), and salivary glands (parotids, 0.031 ± 0.011 mSv/MBq; submandibular, 0.061 ± 0.031 mSv/MBq). Other organs of interest were the bladder (0.102 ± 0.046 mSv/MBq) and kidneys (0.029 ± 0.009 mSv/MBq). Conclusion: Imaging using 18F-TFB imparts a radiation exposure similar in magnitude to many other 18F-labeled radiotracers. 18F-TFB shows a biodistribution similar to 99mTc-pertechnetate, a known nonorganified hNIS tracer, and is pharmacologically and radiobiologically safe in humans. Phase 2 trials for 18F-TFB as an hNIS imaging agent are warranted.
Authors: Edward B Silberstein; Abass Alavi; Helena R Balon; Susan E M Clarke; Chaitanya Divgi; Michael J Gelfand; Stanley J Goldsmith; Hossein Jadvar; Carol S Marcus; William H Martin; J Anthony Parker; Henry D Royal; Salil D Sarkar; Michael Stabin; Alan D Waxman Journal: J Nucl Med Date: 2012-07-11 Impact factor: 10.057
Authors: Dominique Delbeke; R Edward Coleman; Milton J Guiberteau; Manuel L Brown; Henry D Royal; Barry A Siegel; David W Townsend; Lincoln L Berland; J Anthony Parker; Karl Hubner; Michael G Stabin; George Zubal; Marc Kachelriess; Valerie Cronin; Scott Holbrook Journal: J Nucl Med Date: 2006-05 Impact factor: 10.057
Authors: S Mattsson; L Johansson; S Leide Svegborn; J Liniecki; D Noßke; K Å Riklund; M Stabin; D Taylor; W Bolch; S Carlsson; K Eckerman; A Giussani; L Söderberg; S Valind Journal: Ann ICRP Date: 2015-07
Authors: Walter Jentzen; Robert F Hobbs; Alexander Stahl; Jochen Knust; George Sgouros; Andreas Bockisch Journal: Eur J Nucl Med Mol Imaging Date: 2010-01-13 Impact factor: 9.236
Authors: Amanda J Weeks; Maite Jauregui-Osoro; Marcel Cleij; Julia E Blower; James R Ballinger; Philip J Blower Journal: Nucl Med Commun Date: 2011-02 Impact factor: 1.690
Authors: Alex Khoshnevisan; Krisanat Chuamsaamarkkee; Mehdi Boudjemeline; Alex Jackson; Gareth E Smith; Antony D Gee; Gilbert O Fruhwirth; Philip J Blower Journal: J Nucl Med Date: 2016-08-18 Impact factor: 10.057
Authors: J M Marti-Climent; M Collantes; M Jauregui-Osoro; G Quincoces; E Prieto; I Bilbao; M Ecay; J A Richter; I Peñuelas Journal: EJNMMI Res Date: 2015-12-03 Impact factor: 3.138
Authors: Huailei Jiang; Nicholas R Schmit; Alex R Koenen; Aditya Bansal; Mukesh K Pandey; Robert B Glynn; Bradley J Kemp; Kera L Delaney; Angela Dispenzieri; Jamie N Bakkum-Gamez; Kah-Whye Peng; Stephen J Russell; Tina M Gunderson; Val J Lowe; Timothy R DeGrado Journal: EJNMMI Res Date: 2017-10-27 Impact factor: 3.138
Authors: Reona Sakemura; Aditya Bansal; Elizabeth L Siegler; Mehrdad Hefazi; Nan Yang; Roman H Khadka; Alysha N Newsom; Michael J Hansen; Michelle J Cox; Claudia Manriquez Roman; Kendall J Schick; Ismail Can; Erin E Tapper; Wendy K Nevala; Mohamad M Adada; Evandro D Bezerra; Lionel Aurelien Kankeu Fonkoua; Paulina Horvei; Michael W Ruff; Sameer A Parikh; Mukesh K Pandey; Timothy R DeGrado; Lukkana Suksanpaisan; Neil E Kay; Kah-Whye Peng; Stephen J Russell; Saad S Kenderian Journal: Cancer Immunol Res Date: 2021-07-08 Impact factor: 12.020